Inclusion Criteria:  Age ≥18 years old Willing and able to give informed consent Newly diagnosed with CML in chronic phase within 6 months from confirmed diagnosis and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein. Subtype classification whether b3a2 (e14a2) or b2a2 (e13a2) is not required for study eligibility. Minimal prior CML therapy including a TKI for less than 30 days. ECOG performance status 0-2 (appendix 1)  Adequate organ function:  AST and ALT < 3 times the institutional upper limit of normal Creatinine < 1.5 times the institutional upper limit of normal Total bilirubin < 1.5 times the institutional upper limit of normal or < 3.0 x the institutional upper limit of normal with Gilbert Syndrome (unless direct bilirubin is within normal limits)  Female patients must meet one of the following:  Postmenopausal for at least one year before the screening visit, Surgically sterile If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through 90 days after the last dose of study drug, Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)  Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:  Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)  Exclusion Criteria:  Patients with accelerated or blast phase CML (refer to appendix 4) Active second malignancy requiring active treatment History of recent (within 12 months) acute pancreatitis or chronic pancreatitis Subjects who have previously received treatment with asciminib. Subjects with PLT count < 50,000 mm3 or ANC of < 500 mm3 or Hemoglobin < 8 g/dL Lipase > institutional upper limit of normal Pregnant or lactating Taking a strong inhibitors or inducers of CYP3A4 or CYP3A4 substrates with narrow therapeutic index (refer to appendix 6) at time of enrollment Unable to comply with lab appointment schedule and PRO assessments Another investigational drug within 4 weeks of enrollment Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol Patient has undergone a prior allogeneic stem cell transplant Screening 12-lead ECG showing a baseline corrected QT interval >480msec (patients with a pacemaker will still be eligible with QTc>500msec)